RPRX — Royalty Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- $16.83bn
- $25.28bn
- $2.35bn
- 86
- 51
- 71
- 79
Annual cashflow statement for Royalty Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | -94.5 | -11.7 | -213 | -113 | 38.4 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 1,667 | 2,035 | 2,018 | 2,144 | 2,988 |
| Capital Expenditures | -1,721 | -2,182 | -2,192 | -1,742 | -2,116 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -395 | -577 | 321 | 712 | 42.7 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -2,116 | -2,759 | -1,870 | -1,029 | -2,073 |
| Financing Cash Flow Items | -898 | -990 | -602 | -612 | -486 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -1,192 | 1,487 | 385 | -945 | -2,149 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1,641 | 762 | 532 | 170 | -1,234 |